Droloxifene (Synonyms: FK-435, 3-Hydroxytamoxifen, K-060-E) |
Katalog-Nr.GC39707 |
Droloxifen, ein Tamoxifen-Derivat, ist ein oral aktiver und selektiver Östrogenrezeptor-Modulator. Droloxifen zeigt antiÖstrogene und antiimplantative Wirkungen. Droloxifen induziert die p53-Expression und Apoptose in MCF-7-Zellen. Droloxifen verhindert den Knochenschwund bei ovariektomierten Ratten.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 82413-20-5
Sample solution is provided at 25 µL, 10mM.
Droloxifene, a Tamoxifen derivative, is an orally active and selective estrogen receptor modulator. Droloxifene shows antiestrogenic and anti-implantation effects. Droloxifene induces p53 expression and apoptosis in MCF-7 cells. Droloxifene prevents bone loss in ovariectomized rats [1][2][3].
[1]. Herrington DM, et al. Cardiovascular effects of droloxifene, a new selective estrogen receptor modulator, in healthypostmenopausal women. Arterioscler Thromb Vasc Biol. 2000 Jun;20(6):1606-12. [2]. Grasser WA, et al. Common mechanism for the estrogen agonist and antagonist activities of droloxifene. J Cell Biochem. 1997 May;65(2):159-71. [3]. Ke HZ, et al. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. ndocrinology. 1995 Jun;136(6):2435-41. [4]. Huang Y, et al. Anti-implantation effect of droloxifene in rats and its relationship with anti-estrogenic activity. Acta Pharmacol Sin. 2005 Oct;26(10):1243-7.
Average Rating: 5
(Based on Reviews and 5 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *